| Open access publishing and the future of scientific communication CH Hawkes, G Giovannoni, J Lechner-Scott, M Levy, A Yeh Multiple sclerosis and related disorders 86, 2024 | | 2024 |
| Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified? G Giovannoni, CH Hawkes, J Lechner-Scott, M Levy, EA Yeh, G Pepper, ... Multiple sclerosis and related disorders 87, 105698, 2024 | | 2024 |
| Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse BP Trewin, RC Dale, J Qiu, M Chu, N Jeyakumar, FD Cruz, J Andersen, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | | 2024 |
| Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries S Sharmin, I Roos, CB Malpas, P Iaffaldano, M Simone, M Filippi, ... The Lancet Child & Adolescent Health 8 (5), 348-357, 2024 | 2 | 2024 |
| Where does multiple sclerosis come from? VE Maltby, RJ Scott, G Giovannoni, CH Hawkes, M Levy, EA Yeh, ... Multiple Sclerosis and Related Disorders 85, 2024 | | 2024 |
| Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study C Dekeyser, M Hautekeete, M Cambron, V Van Pesch, F Patti, J Kuhle, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | | 2024 |
| Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase T Spelman, S Eichau, R Alroughani, S Ozakbas, SJ Khoury, F Patti, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 10 (2 …, 2024 | | 2024 |
| OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool EA Yeh, G Giovannoni, C Hawkes, RC Sergott, M Levy, J Lechner-Scott Multiple sclerosis and related disorders 84, 2024 | | 2024 |
| A pro-inflammatory diet is associated with long-term depression and anxiety levels but not fatigue in people with multiple sclerosis A Saul, BV Taylor, L Blizzard, S Simpson-Yap, WH Oddy, N Shivappa, ... Multiple Sclerosis and Related Disorders 84, 105468, 2024 | 2 | 2024 |
| Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome H Butzkueven, AL Ponsonby, MS Stein, RM Lucas, D Mason, S Broadley, ... Brain 147 (4), 1206-1215, 2024 | 5 | 2024 |
| No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry MP Campagna, EK Havrdova, D Horakova, G Izquierdo, F Matesanz, ... Multiple Sclerosis Journal, 13524585241240406, 2024 | | 2024 |
| Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 YC Foong, D Merlo, M Gresle, K Buzzard, M Zhong, WZ Yeh, V Jokubaitis, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | 1 | 2024 |
| Improvement of the thalamocortical white matter network in people with stable treated relapsing–remitting multiple sclerosis over time A Alshehri, N Koussis, O Al‐iedani, I Khormi, R Lea, S Ramadan, ... NMR in Biomedicine, e5119, 2024 | | 2024 |
| In the era of antiviral trials for MS, the answer lies in the details N Drosu, K Bjornevik, PA Bilodeau, A Yeh, J Lechner-Scott, CH Hawkes, ... Multiple sclerosis and related disorders 82, 2024 | 1 | 2024 |
| The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease G Liyanage, BP Trewin, JA Lopez, J Andersen, F Tea, V Merheb, ... Journal of Neurology, Neurosurgery & Psychiatry, 2024 | 1 | 2024 |
| What is the role of diet for multiple sclerosis? Why epidemiological studies don't give the full answer J Lechner-Scott, Y Probst, G Giovannoni, CH Hawkes, M Levy, EA Yeh Multiple sclerosis and related disorders, 105457, 2024 | | 2024 |
| Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme TA Hardy, P Aouad, MH Barnett, S Blum, S Broadley, WM Carroll, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 10 (1 …, 2024 | | 2024 |
| Multi-modal neuroimaging signatures predict cognitive decline in multiple sclerosis: A 5-year longitudinal study O Al-Iedani, S Lea, A Alshehri, VE Maltby, B Saugbjerg, S Ramadan, ... Multiple sclerosis and related disorders 81, 105379, 2024 | 1 | 2024 |
| Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis G Giovannoni, CH Hawkes, J Lechner-Scott, M Levy, EA Yeh Multiple Sclerosis and Related Disorders 81, 2024 | 1 | 2024 |
| A longitudinal analysis of brain volume changes in myelin oligodendrocyte glycoprotein antibody‐associated disease M Amin, O Al‐iedani, RA Lea, F Brilot, VE Maltby, J Lechner‐Scott Journal of Neuroimaging 34 (1), 78-85, 2024 | 1 | 2024 |
